Scan to Download
Max Healthcare Q2 Highlights (Consolidated, YoY)
Revenue rises 25.3% to Rs 1,707 crore versus Rs 1,363 crore.
Ebitda rises16.3% at Rs 451 crore versus Rs 387 crore.
Margin at 26.4% vs 28.4%.
Net profit up 1.9% at Rs 282 crore versus Rs 277 crore.
CCL Products Q2 Highlights (Consolidated, YoY)
Revenue up 21.5% to Rs 738.20 crore versus Rs 607.57 crore.
Net profit up 22% to Rs 73.95 crore versus Rs 60.86 crore.
Ebitda up 25% to Rs 137.08 crore versus Rs 109.91 crore.
Margin at 18.6% versus 18.1%.
Insurance Premium stood at Rs 5,450 Cr insurance. While new core online insurance premium was up 61%, new health and life insurance premium was up 69%.
Source: Press Release
PB Fintech Q2 Highlights (Consolidated, QoQ)
Revenue up 15.5% to Rs 1,167.23 crore versus Rs 1,010.49 crore.
Net profit down 15% to Rs 50.98 crore versus Rs 59.98 crore.
Ebitda loss at Rs 7.79 crore versus Ebitda loss of Rs 39.25 crore.
Potential order pipeline of Mazagon Dock includes additional Scorpene submarines.
ONGC offshore project will be executed at Rs 7,000-8,000 crore in over two years.
Current capacity of the company includes 11 submarines and 10 warships.
The company is currently executing six large platforms and some smaller vessels.
Source: Earnings Concall
Mazagon Dock expects revenue growth of 10-12% year-over-year, the management said on Tuesday. The company also expects normalized PBT margins of 12-15% for new projects.
Expects to maintain margins in the second half of this fiscal around the margins in the first half of financial year 2025.
Source: Earnings Concall
Mazagon Dock has two deliveries planned before Dec. 31 that include one submarine and potentially one destroyer ahead of schedule.
Delivery of a second frigate may slip to the next financial year, the management said on Tuesday.
No reversal of liquidated damages occurred in the second quarter of this fiscal.
Source: Earnings Concall
Timken India Q2 Highlights (YoY)
Revenue up 10.4% to Rs 752.89 crore versus Rs 681.98 crore.
Net profit down 3% to Rs 89.95 crore versus Rs 93.05 crore.
Ebitda down 2% to Rs 133.35 crore versus Rs 135.51 crore.
Margin at 17.7% versus 19.9%.
Sundram Fasteners Q2 Highlights (Consolidated, YoY)
Revenue up 4.5% to Rs 1,486.04 crore versus Rs 1,421.82 crore.
Net profit up 8% to Rs 143.84 crore versus Rs 133.05 crore.
Ebitda up 6% to Rs 244.63 crore versus Rs 230.73 crore.
Margin at 16.5% versus 16.2%.
Muthoot Microfin Q2 Highlights (Consolidated, YoY)
Total income rises 18% at Rs 667 crore versus Rs 565 crore.
Net profit falls 43.7% at Rs 61.6 crore versus Rs 110 crore.
eClerx Services Q2 Highlights (Consolidated, YoY)
Revenue up 6.4% to Rs 831.84 crore versus Rs 781.92 crore.
Net profit up 24% to Rs 139.50 crore versus Rs 112.05 crore.
Ebit up 36% to Rs 182.87 crore versus Rs 134.71 crore.
Margin at 22.0% versus 17.2%.
Chemplast Sanmar Q2 Highlights (Consolidated, YoY)
Revenue up 0.5% to Rs 992.75 crore versus Rs 987.75 crore.
Net loss at Rs 31.26 crore versus Rs 26.05 crore.
Ebitda down 44% to Rs 25.80 crore versus Rs 45.95 crore.
Margin at 2.6% versus 4.7%.
Triveni Engineering & Industries Q2 Highlights (Consolidated, YoY)
Revenue up 8.1% to Rs 1,490.95 crore versus Rs 1,408.84 crore.
Net loss at Rs 22.42 crore versus profit of Rs 29.11 crore.
Ebitda down 93% to Rs 4.64 crore versus Rs 62.93 crore.
Margin at 0.3% versus 4.5%.
Oil India Q2 Highlights (Consolidated, QoQ)
Revenue down 13.0% to Rs 7,247.03 crore versus Rs 8,120.21 crore.
Net profit up 3% to Rs 2,069.16 crore versus Rs 2,016.30 crore.
Ebitda down 19% to Rs 2,535.83 crore versus Rs 3,141.95 crore.
Margin at 35.0% versus 38.7%.
GAIL India Q2 Highlights (Consolidated, QoQ)
Revenue down 2.4% to Rs 33,888.90 crore versus Rs 34,737.77 crore.
Net profit down 16% to Rs 2,689.67 crore versus Rs 3,183.35 crore.
Ebitda down 18% to Rs 3,937.20 crore versus Rs 4,790.02 crore.
Margin at 11.6% versus 13.8%.
Waaree Renewable Technologies Q2 Highlights (Consolidated, YoY)
Revenue up 249.5% to Rs 524.46 crore versus Rs 150.06 crore.
Net profit up 161% to Rs 53.52 crore versus Rs 20.54 crore.
Ebitda up 133% to Rs 71.56 crore versus Rs 30.67 crore.
Margin at 13.6% versus 20.4%.
Dr. Reddy's Laboratories Europe revenue rose 9% year-on-year to Rs 5.8 billion on account of leveraging the portfolio to launch new products, partly offset by price erosion. Sequentially it rose 10% on the back of new product launches.
Europe's revenue in the first half rose 7% year-on-year to Rs 11 billion on account of new product launches and momentum in base business, partly offset by price erosion.
Source: Press Release
Dr. Reddy's Laboratories North America revenue rose 17% year-on-year to Rs 37.3 billion driven by improved sales volumes, partly offset by price erosion. Sequentially it fell 3% due to decrease in sales volume.
North America revenue in the first half rose 19% year-on-year to Rs 75.7 billion driven by increase in sales.
Source: Press Release
Dr. Reddy's Laboratories global generics revenue rose 17% year-on-year to Rs 71.6 billion driven by improved sales volumes and new product launches. Sequentially it grew 4% with growth primarily driven by Emerging Markets and Europe.
Global generics revenue in the first half rose 16% year-on-year to Rs 14.04 crore driven by increase in sales across all markets.
Source: Press Release
Titan expects the second half of this fiscal be better than the first half.
If the lab grown jewellery amount goes beyond Rs 1 lakh, customer interest drops significantly, the management said on Tuesday.
"Nothing is stopping us from entering lab grown diamond space, we have not launched it yet considering market trends - we will speak about it when its time," the management added.
Source: Earnings Concall
Titan's buyer growth in the studded jewelley is strong the management said on Tuesday.
The company further added that the ticket size in gold has remained unchanged, while the ticket size in solitaire has been affected.
The company is keeping a close track on lab grown diamonds.
Margins in financial year 2025 to be in the range of 11-11.5%
Trent is a big retailer and has a diversified business, hence it makes sense for it to enter lab grown diamond space
Non solitaire diamonds demand remains unimpacted.
Source: Earnings Concall
Dr. Reddy's Laboratories Q2 Results: Profit Falls 9%, Misses Estimates
Titan margins have taken a hit on account of one-time custom duty loss partly in this quarter and partly in next quarter, lower studded mix and large carat solitaire diamond stone demand is affected to international demand supply pressure.
Source: Earnings Concall
JK Tyre & Industries Q2 Highlights (Consolidated, YoY)
Revenue down 7.1% to Rs 3,621.56 crore versus Rs 3,897.53 crore.
Net profit down 44% to Rs 139.75 crore versus Rs 248.62 crore.
Ebitda down 28% to Rs 421.26 crore versus Rs 589.14 crore.
Margin at 11.6% versus 15.1%.
Mankind Pharma Q2 Results: Profit Jumps 29%, Beats Estimates
Berger Paints Q2 Highlights (Consolidated, YoY)
Revenue up 0.3% to Rs 2,774.61 crore versus Rs 2,767.30 crore.
Net profit down 8% to Rs 269.90 crore versus Rs 292.13 crore.
Ebitda down 8% to Rs 434.18 crore versus Rs 473.65 crore.
Margin at 15.6% versus 17.1%.
Titan Q2 Results: Profit Falls 23%, Misses Estimates
Titan Q2 Highlights (Consolidated, YoY)
Revenue up 16.0% to Rs 14,534.00 crore versus Rs 12,529.00 crore.
Net profit down 23% to Rs 704.00 crore versus Rs 916.00 crore.
Ebitda down 12% to Rs 1,236.00 crore versus Rs 1,411.00 crore.
Margin at 8.5% versus 11.3%.
Dr. Reddy’s Laboratories Q2 Highlights (Consolidated, YoY)
Revenue up 16.5% to Rs 8,038.20 crore versus Rs 6,902.60 crore.
Net profit down 9% to Rs 1,341.90 crore versus Rs 1,482.20 crore.
Ebitda up 3% to Rs 2,076.50 crore versus Rs 2,008.30 crore.
Margin at 25.8% versus 29.1%.
Datamatics Global Services Q2 Highlights (Consolidated, QoQ)
Revenue up 3.2% to Rs 406.75 crore versus Rs 393.99 crore.
Net profit down 4% to Rs 42.20 crore versus Rs 43.82 crore.
Ebit down 8% to Rs 39.34 crore versus Rs 42.60 crore.
Margin at 9.7% versus 10.8%.
Manappuram Finance Q2 Highlights (Consolidated, YoY)
Total income rises 21.3% at Rs 2,637 crore versus Rs 2,174 crore.
Net Profit up 2% at Rs 572 crore versus Rs 561 crore.
Shares of SJVN gained 4.88% to Rs 116.85 apiece, before paring gains to trade 2.26% higher at Rs 113.93 by 3:12 p.m. after the company reported a 16.8% increase in revenue to Rs 1,026 crore. The benchmark NSE Nifty 50 was trading 0.91% higher.
The stock has risen 55.11% in the last 12 months and 22.55% on a year-to-date basis. The total traded volume so far in the day stood at 1.4 times its 30-day average. The relative strength index was at 43.
Three out of the five analysts tracking SJVN have a 'buy' rating on the stock, while one suggests a hold and one suggests a 'sell', according to Bloomberg data. The average of 12-month analyst price targets implies a potential downside of 14.7%.
Revenue up 4.2% At Rs 772 crore versus Rs 741 crore.
Ebitda down 2.8% at Rs 123 crore versus Rs 127 crore.
Margin at 15.9% versus 17.1%.
Net Profit down 11.4% at Rs 65.5 crore versus Rs 73.9 crore.
Revenue up 16.8% at Rs 1,026 crore versus Rs 878 crore.
Ebitda up 17.3% at Rs 828 crore versus Rs 706 crore.
Margin at 80.7% versus 80.4%.
Net profit up 0.1% at Rs 439.9 crore versus Rs 439.6 crore.
Revenue down 1.2% at Rs 917 crore versus Rs 928 crore.
Ebitda up 15.7% at Rs 81.2 crore versus Rs 70.2 crore.
Margin at 8.8% versus 7.6%.
Net profit at Rs 185 crore versus Rs 51 crore.
Shares of Mazagon Dock spiked as much as 7.23% to Rs 4318 apiece after the PSU reported a 75% uptick in net profit, beating estimates.
Revenue up 17.8% at Rs 415 crore versus Rs 352 Cr
Ebitda up 52.4% at Rs 73.6 crore versus Rs 48.3 crore.
Margin at 17.7% versus 13.7%.
Net profit up 74.5% At Rs 47.5 crore versus Rs 27.2 crore.
Mazagon Dock Q2 Results: Profit Up 76%, Beats Estimates
KPR Mill Q2 Highlights (Consolidated, YoY)
Revenue down 2.1% at Rs 1,480 crore versus Rs 1,511 crore.
Ebitda down 0.5% at Rs 296 crore versus Rs 298 crore.
Margin at 20% versus 19.7%.
Net profit up 1.5% at Rs 205 crore versus Rs 202 crore.
Revenue up 40.3% at Rs 242 crore versus Rs 172 crore.
Ebitda flat at Rs 60.8 crore.
Margin at 25.1% versus 35.3%.
Net profit down 6.3% at Rs 44.9 crore versus Rs 47.9 crore.
Mankind Pharma is expected to announce a net profit of Rs 600 crore, with revenue estimated at Rs 3,050 crore and an Ebitda of Rs 781 crore, reflecting a margin of 25.6%.
In the preceding quarter, Mankind Pharma had reported consolidated revenue from operations of Rs 2,893.42 crore, up 12.2% YoY. Net profit increased nearly 10% over the previous year to Rs 543.1 crore in Q1 compared to Rs 494.2 crore in the same quarter last year.
Oil India is likely to report a standalone net profit of Rs 1,933 crore and revenue of Rs 5,292 crore.
In its June quarter results, Oil India had exceeded analysts’ estimates in terms of consolidated net profit. The profit after tax, or net profit, fell 14% YoY in the first quarter to Rs 2,016.3 crore against Rs 2,332.94 crore in the June quarter of the preceding fiscal.
Titan is expected to report a net profit of Rs 969 crore, with revenue projected at Rs 13,425 crore, as per analysts' consensus estimate compiled by Bloomberg. The company’s Ebitda is estimated at Rs 1,566 crore, resulting in an Ebitda margin of 11.7%.
In the first quarter, the company's consolidated profit-after-tax declined 5.5% year-on-year in the first quarter of financial year 2025 to Rs 715 crore versus Rs 756 crore in the year-ago period.
Titan Q1 FY25 Highlights (Consolidated, YoY)
Total income up 11.2% to Rs 12,308 crore versus Rs 11,069 crore.
Profit-after-tax down 5.5% to Rs 715 crore versus Rs 756 crore.
Ebitda up 10.3% to Rs 1,367 crore versus Rs 1,239 crore.
Ebitda margin at 11.1% versus 11.2%.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
